Patents by Inventor Barbara A. Thorne

Barbara A. Thorne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10696952
    Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: June 30, 2020
    Assignee: Genzyme Corporation
    Inventors: Paulene Mclean Quigley Sheldon, Peter S. Gagnon, Gina Nichols, Barbara A. Thorne
  • Patent number: 10400042
    Abstract: A method for conversion of an N-terminal glutamine and/or glutamic acid residue of a protein to pyro-glutamic acid within a purification process.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: September 3, 2019
    Assignee: MABXIENCE RESEARCH, S.L.
    Inventors: Marie Rose Van Schravendijk, Stephen Waugh, Barbara Thorne
  • Publication number: 20190010468
    Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.
    Type: Application
    Filed: June 12, 2018
    Publication date: January 10, 2019
    Inventors: Pauline McLean Quigley SHELDON, Peter S. GAGNON, Gina NICHOLS, Barbara A. THORNE
  • Patent number: 10017746
    Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: July 10, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Pauline McLean Quigley Sheldon, Peter S. Gagnon, Gina Nichols, Barbara A. Thorne
  • Publication number: 20180116197
    Abstract: The present invention relates to termite preferred resource compositions and methods. In embodiments, the present invention is directed to termite preferred resource compositions including materials from a Sabal palm tree material (Sabalpalmetto; Family Arecaceae) and a pesticide toxic to one or more species of termites. In additional embodiment's, the present invention is directed to a method of creating a termite assurance program to limit termite damage to a structure including the steps of providing an initial investigation of termite detection, damage, or activity for a structure; placing a termite station comprising a housing, at least one entry point in the housing allowing for ingress and egress of a termite, and materials from a Sabal palm tree contained within the housing in an area proximate the structure, and inspecting the termite station for live termites or evidence of termite activity after it is placed.
    Type: Application
    Filed: March 24, 2016
    Publication date: May 3, 2018
    Inventor: Barbara Thorne
  • Publication number: 20160060349
    Abstract: A method for conversion of an N-terminal glutamine and/or glutamic acid residue of a protein to pyro-glutamic acid within a purification process.
    Type: Application
    Filed: April 3, 2014
    Publication date: March 3, 2016
    Inventors: Marie Rose VAN SCHRAVENDIJK, Stephen WAUGH, Barbara THORNE
  • Publication number: 20150024467
    Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.
    Type: Application
    Filed: December 16, 2011
    Publication date: January 22, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Pauline McLean Quigley Sheldon, Peter S. Gagnon, Gina Nichols, Barbara A. Thorne
  • Patent number: 7214493
    Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: May 8, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure Kunkel, Subinay Ganguly, Ralph Abraham, Diane L. Hollenbaugh, Jill Rillema, Barbara Thorne, Walter W. Shuford, Robert S. Mittler
  • Publication number: 20050202022
    Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Application
    Filed: March 7, 2005
    Publication date: September 15, 2005
    Inventors: Maria Kunkel, Subinay Ganguly, Ralph Abraham, Diane Hollenbaugh, Jill Rillema, Barbara Thorne, Walter Shuford, Robert Mittler
  • Patent number: 6887673
    Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: May 3, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure Kunkel, Subinay Ganguly, Ralph Abraham, Diane L. Hollenbaugh, Jill Rillema, Barbara Thorne, Walter W. Shuford, Robert S. Mittler
  • Publication number: 20040105855
    Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Application
    Filed: July 30, 2003
    Publication date: June 3, 2004
    Inventors: Maria Jure Kunkel, Subinay Ganguly, Ralph Abraham, Diane L. Hollenbaugh, Jill Rillema, Barbara Thorne, Walter W. Shuford, Robert S. Mittler
  • Patent number: 6413514
    Abstract: A method for the treatment of T cell mediated disorders is described. The method involves administering to a subject a therapeutically effective amount of an anti-human CD40 antibody. Disease states suitable for treatment with this method include graft versus host disease and transplant rejection and auto immune disease such as type I diabetes, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myesthenia gravis.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: July 2, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alejandro A. Aruffo, Diane Hollenbaugh, Anthony W. Siadak, Karen K. Berry, Linda Harris, Barbara A. Thorne, Jurgen Bajorath
  • Patent number: 6312693
    Abstract: The Applicants have discovered humanized anti-human CD40 antibodies which block the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transplantation, and are also useful for their anti-inflammatory properties.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: November 6, 2001
    Inventors: Alejandro A. Aruffo, Diane Hollenbaugh, Anthony W. Siadak, Karen K. Berry, Linda Harris, Barbara A. Thorne, Jurgen Bajorath, William D. Huse, Herren Wu, Jeffry D. Watkins
  • Patent number: 6051228
    Abstract: The Applicants have discovered a novel antibody, more specifically a chimerized anti-human CD40 monoclonal antibody, which blocks the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transplantation, and are also useful for their anti-inflammatory properties.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: April 18, 2000
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Alejandro A. Aruffo, Diane Hollenbaugh, Anthony W. Siadak, Karen K. Berry, Linda Harris, Barbara A. Thorne, Jurgen Bajorath